Kanwal Raghav

机构：The University of Texas MD Anderson Cancer Center · ORCID：0000-0003-1311-4173

发表论文 529 篇 · 总被引 9341 次 · h-index 48

代表论文

• YAP/TEAD inhibitor VT3989 in solid tumors: a phase 1/2 trial (2025 · Nature Medicine · 被引 48)
• Precemtabart tocentecan, an anti-CEACAM5 antibody–drug conjugate, in metastatic colorectal cancer: a phase 1 trial (2025 · Nature Medicine · 被引 19)
• Advances in Targeting HER2 across Cancer Subtypes: A Pan-Tumor Approach (2025 · Clinical Cancer Research · 被引 5)
• Amivantamab Monotherapy in Chemorefractory RAS / BRAF Wild-Type Metastatic Colorectal Cancer: Results From OrigAMI-1, an Open-Label, Phase Ib/II Study (2026 · Journal of Clinical Oncology · 被引 2)
• 737MO Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic colorectal cancer (mCRC): Final analysis of DESTINY-CRC02, a randomized, phase II trial (2025 · Annals of Oncology · 被引 2)
• 123P Cancer signal origin (CSO) prediction in cancer of unknown primary (CUP) syndrome (CRONUS) using circulating tumor DNA (ctDNA) (2025 · Annals of Oncology · 被引 1)